MX2011009359A - Conjugados hapteno-portador con toxinas bacterianas que tienen un peptido señal como portador, y su uso en composiciones inmunogenas. - Google Patents
Conjugados hapteno-portador con toxinas bacterianas que tienen un peptido señal como portador, y su uso en composiciones inmunogenas.Info
- Publication number
- MX2011009359A MX2011009359A MX2011009359A MX2011009359A MX2011009359A MX 2011009359 A MX2011009359 A MX 2011009359A MX 2011009359 A MX2011009359 A MX 2011009359A MX 2011009359 A MX2011009359 A MX 2011009359A MX 2011009359 A MX2011009359 A MX 2011009359A
- Authority
- MX
- Mexico
- Prior art keywords
- carrier
- immunogenic compositions
- hapten
- signal peptide
- bacterial toxins
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Addiction (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20962909P | 2009-03-09 | 2009-03-09 | |
| PCT/EP2010/052997 WO2010103017A2 (en) | 2009-03-09 | 2010-03-09 | Hapten-carrier conjugates with bacterial toxins having a signal peptide as carrier and their use in immunogenic compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011009359A true MX2011009359A (es) | 2011-12-16 |
Family
ID=42555592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011009359A MX2011009359A (es) | 2009-03-09 | 2010-03-09 | Conjugados hapteno-portador con toxinas bacterianas que tienen un peptido señal como portador, y su uso en composiciones inmunogenas. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20120100171A1 (enExample) |
| EP (1) | EP2405943A2 (enExample) |
| JP (1) | JP2012519724A (enExample) |
| KR (1) | KR20120022760A (enExample) |
| CN (1) | CN102427828A (enExample) |
| CA (1) | CA2754592A1 (enExample) |
| MX (1) | MX2011009359A (enExample) |
| RU (1) | RU2011140858A (enExample) |
| WO (1) | WO2010103017A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8728478B2 (en) * | 2008-09-03 | 2014-05-20 | Board Of Trustees Of Michigan State University | Immunogenic Escherichia coli heat stable enterotoxin |
| ES2732815T3 (es) | 2009-05-22 | 2019-11-26 | Genocea Biosciences Inc | Vacunas frente al virus del herpes simple de tipo 2: composiciones y métodos para provocar una respuesta inmunitaria |
| EP2482838A4 (en) * | 2009-09-30 | 2013-04-10 | Toxcure Inc | USE OF BOTULINUM NEUROTOXIN FOR THE TREATMENT OF SUBSTANCE DEPENDENCE |
| CA2856697A1 (en) | 2010-11-24 | 2012-06-07 | Genocea Biosciences, Inc. | Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response |
| WO2012125720A2 (en) | 2011-03-14 | 2012-09-20 | University Of Louisville Research Foundation, Inc. | Polypeptides having immunoactivating activity and methods of producing the same |
| EP3313866B1 (en) | 2015-06-29 | 2024-11-20 | University Of Louisville Research Foundation, Inc. | Compositions and methods for treating cancer and promoting wound healing |
| JP2019537555A (ja) | 2016-09-28 | 2019-12-26 | ジェノセア バイオサイエンシーズ， インコーポレイテッド | ヘルペスを処置するための方法および組成物 |
| WO2018060351A1 (en) * | 2016-09-29 | 2018-04-05 | Ipsen Biopharm Limited | Hybrid neurotoxins |
| EP3973253A4 (en) * | 2019-05-20 | 2022-08-10 | Siemens Healthcare Diagnostics, Inc. | PROCEDURE FOR DETECTING ABERRANTIC RESULTS DUE TO INCOMPLETE DELIVERY OF A POLYHAPTEN REAGENT IN IMMUNOASSAYS |
| JP7555363B2 (ja) | 2019-07-03 | 2024-09-24 | インターベット インターナショナル ベー． フェー． | マイコトキシン症に対する防御のためのコンジュゲート化デオキシニバレノール |
| US12343375B2 (en) | 2021-02-09 | 2025-07-01 | University Of Louisville Research Foundation, Inc. | Spray dried formulation of a cholera toxin B subunit variant |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5171568A (en) | 1984-04-06 | 1992-12-15 | Chiron Corporation | Recombinant herpes simplex gb-gd vaccine |
| US4883761A (en) | 1986-03-25 | 1989-11-28 | The United States Of America As Represented By The Department Of Health And Human Services | Pertussis toxin gene: cloning and expression of protective antigen |
| EP0251575B2 (en) | 1986-06-17 | 2002-11-13 | Chiron Corporation | Hepatitis delta diagnostics and vaccines, their preparation and use |
| WO1989004669A1 (en) | 1987-11-18 | 1989-06-01 | Chiron Corporation | Nanbv diagnostics and vaccines |
| WO1990011089A1 (en) | 1989-03-17 | 1990-10-04 | Chiron Corporation | Nanbv diagnostics and vaccines |
| ATE211772T1 (de) | 1989-05-18 | 2002-01-15 | Chiron Corp | Nanbv-diagnostika: polynukleotide, geeignet für reihenuntersuchungen auf hepatitis c-virus |
| US5840307A (en) * | 1995-03-31 | 1998-11-24 | Immulogic Pharmacuetical Corp. | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation |
| US5876727A (en) | 1995-03-31 | 1999-03-02 | Immulogic Pharmaceutical Corporation | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same |
| US20020032316A1 (en) | 1995-03-31 | 2002-03-14 | Cantab Pharmaceuticals Research Limited | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same |
| FR2768747B1 (fr) | 1997-09-19 | 2000-12-01 | Pasteur Institut | Acides nucleiques, cellules recombinantes, et procede de preparation de compositions immunogenes |
| CN1231586C (zh) * | 2003-04-15 | 2005-12-14 | 中国科学院微生物研究所 | 一种多形汉逊酵母表达重组霍乱毒素b亚单位基因及其应用 |
| GB0325494D0 (en) * | 2003-10-31 | 2003-12-03 | Sbl Vaccin Ab | Expression system |
-
2010
- 2010-03-09 KR KR1020117023547A patent/KR20120022760A/ko not_active Withdrawn
- 2010-03-09 MX MX2011009359A patent/MX2011009359A/es not_active Application Discontinuation
- 2010-03-09 WO PCT/EP2010/052997 patent/WO2010103017A2/en not_active Ceased
- 2010-03-09 RU RU2011140858/15A patent/RU2011140858A/ru not_active Application Discontinuation
- 2010-03-09 JP JP2011553432A patent/JP2012519724A/ja active Pending
- 2010-03-09 CA CA2754592A patent/CA2754592A1/en not_active Abandoned
- 2010-03-09 CN CN2010800175877A patent/CN102427828A/zh active Pending
- 2010-03-09 EP EP10706688A patent/EP2405943A2/en not_active Withdrawn
- 2010-03-09 US US13/255,262 patent/US20120100171A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010103017A2 (en) | 2010-09-16 |
| KR20120022760A (ko) | 2012-03-12 |
| JP2012519724A (ja) | 2012-08-30 |
| US20120100171A1 (en) | 2012-04-26 |
| CN102427828A (zh) | 2012-04-25 |
| CA2754592A1 (en) | 2010-09-16 |
| RU2011140858A (ru) | 2013-04-20 |
| EP2405943A2 (en) | 2012-01-18 |
| WO2010103017A3 (en) | 2010-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2011009359A (es) | Conjugados hapteno-portador con toxinas bacterianas que tienen un peptido señal como portador, y su uso en composiciones inmunogenas. | |
| NZ610976A (en) | Anti-mesothelin antibodies and immunoconjugates | |
| MX2011012665A (es) | Metodos para identificacion de sitios para conjugacion de igg. | |
| MX350200B (es) | Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74. | |
| MX2013001527A (es) | Nuevas vacunas adyuvantes en base a adyuvantes de orientacion para anticuerpos directamente hacia celulas presentadoras de antigenos. | |
| MY157473A (en) | Antibody molecules having specificity for human ox40 | |
| IN2012DN04908A (enExample) | ||
| MX2009001412A (es) | Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas. | |
| MY169837A (en) | Immunogenic compositions of staphylococcus aureus antigens | |
| CL2012002195A1 (es) | Composicion inmunogénica que comprende una mezcla de conjugados de polisacaridos-proteina multivalente que consiste en polisacáridos capsulares de streptococcus pneumoniae; metodo para inducir una respuesta inmune a un polisacarido capsular de streptococcus pneumoniae. | |
| WO2012027365A3 (en) | Targeted multi-epitope dosage forms for induction of an immune response to antigens | |
| EA201290134A1 (ru) | Система экспрессии | |
| MX2013013111A (es) | Composicion inmunogenica que presenta antigeno multiple, y metodos y usos de la misma. | |
| MX354924B (es) | Molecula portadora que comprende un antigeno spr0096 y un spr2021. | |
| NZ610239A (en) | Cross-linkers and their uses | |
| TR201900176T4 (tr) | Anti-TROP2 antikor-ilaç konjugatı. | |
| NO20083066L (no) | Antistoffmolekyler med spesifisitet for human-IL-6 | |
| PH12015500977A1 (en) | Anti-il-13 receptor alpha 2 antibodies and antibody-drug conjugates | |
| MX2009004468A (es) | Novedosas formulaciones para vacunas de peptidos asociados a tumores, unidos a moleculas del antigeno de leucocito humano (hla) de clase i o ii. | |
| MX2007002787A (es) | Adyuvante de glicosilceramida para antigenos de sacarido. | |
| FR2919804B1 (fr) | Composition et vaccin therapeutique anti-tumoral | |
| MX358391B (es) | Moleculas que son anticuerpos con especificidad por ox40 humano. | |
| PH12013500453B1 (en) | Non-lipidated variants of neisseria meningitidis orf2086 antigens | |
| MX2015002482A (es) | Composicion inmunogenica. | |
| WO2013022808A3 (en) | Immunogenic protein conjugates and methods for making and using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |